PROTEIN-tyrosine kinase inhibitorsDRUG resistance in cancer cellsSimple Summary: This manuscript focuses on improving the treatment of non-small cell lung cancer, with actionable gene alterations. The aim is to understand how the treatment with Tyrosine Kinase Inhibitors (TKIs) can be ...
Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S... Mutations in the tyrosine kinase domain of epidermal growth factor receptor (EGFR), including L858R/T790M double and L858R/T790M/C797S triple...
The nano-TiO2aerosol concentration was determined to be 12.35 ± 0.13 mg/m3(Fig.1A). The ELPI High Resolution data indicated a Geometric Count Median Diameter of 170 nm with a Geometric Standard Deviation of 1.95 (Fig.1B). The SMPS and APS data were combined to determine the Geometri...
Here, we review the latest studies describing the features and types of EGFR pathogenic mutations, currently established EGFR-tyrosine kinase inhibitors from the first to fourth generation, including their action mechanisms, acquired resistance, and clinical applications, and potential challenges and ...
Tyrosine Kinase Inhibitors for the Treatment of EGFR Mutation-Positive Non–Small-Cell Lung Cancer: A Clash of the Generationsdoi:10.1016/j.cllc.2019.12.003Riyaz ShahJason F Lester
Mutationsin epidermal growth factor receptor (EGFR) are found in approximately 48% of Asian and 19% of Western patients with lung adenocarcinoma (LUAD), leading to aggressive tumor growth. While tyrosine kinase inhibitors (TKIs) like gefitinib and osimertinib target thi...
Activating somatic mutations in the epidermal growth factor receptor (EGFR) gene are frequently seen in the tumors of light- and never-smoking patients with non-small-cell lung cancer (NSCLC), and the presence of these mutations predicts for objective responses to EGFR tyrosine kinase inhibitors ...
Mutationsin epidermal growth factor receptor (EGFR) are found in approximately 48% of Asian and 19% of Western patients with lung adenocarcinoma (LUAD), leading to aggressive tumor growth. While tyrosine kinase inhibitors (TKIs) like gefitinib and osimertinib target this mutation, treatments often ...